Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06813664

ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network

Toronto, Ontario, M5G 2M9, Canada

Location contact

Jillian Tsai

CONTACT

[email protected]

416-946-4501 ext. 4866

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older.
  • Able to do most daily activities (ECOG 0-2).
  • Able and willing to sign an informed consent form to join the study.
  • Metastatic disease detected on imaging and histologically confirmed NSCLC on first-line TKI therapy
  • Willing to give a blood sample for ctDNA analysis.
  • No upper limit to the number of total metastatic sites, but a maximum of five progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extracranial
  • Prior radiation therapy near progressive lesions is allowed if applicable.
  • All sites of oligoprogression that can be safely treated with SBRT or hypofractionated ablative radiotherapy
  • Oligoprogressive disease is evaluated independently for each lesion using specific criteria.
  • Stable brain metastases allowed if asymptomatic and do not require corticosteroids.
  • Oligoprogressive lesions previously treated with external beam radiation are eligible as long they are clinically asymptomatic, and re-treatment is possible according to the investigator. Prior conventional, non-stereotactic radiotherapy for palliative -purposes is allowed, and if the palliated lesion subsequently progressed but remains asymptomatic and does not require immediate radiotherapy, the lesion can still be counted toward one of the five oligoprogressive lesions
  • Participant is able (i.e. sufficiently fluent or with the assistance of a translator) and willing to complete the quality of life and/or health utility questionnaires in English
  • Accessible for treatment and follow-up.

Exclusion criteria

  • More than 5 extracranial sites of progressive disease.
  • Pregnant.
  • Leptomeningeal disease.
  • Serious health issues that prevent radiotherapy, like ataxia-telangiectasia or scleroderma.
  • Prior radiation therapy near the progressive lesion that would prevent treatment with SBRT due to exceeding limits of healthy tissue tolerance.
  • Any other condition that the investigator believes makes participation in the study inappropriate.

Treatment and study plan

Radiotherapy

Radiation

SBRT/high-dose radiotherapy Standard of care targeted therapy

Primary outcomes

  1. Progression-free-survival

    Time frame: 1 year

    Progression-free-survival 1 (PFS1) will be determined from the first day of SBRT to oligoprogressive sites to the day of diagnosis of radiological progression in the subsequent imaging (irrespective of change in systemic therapy in group B, essentially second-line) or death

Secondary outcomes

  1. Subsequent progression-free-survival

    Time frame: 1 year

    Subsequent PFS will be calculated from the date of first radiological progression after SBRT to second radiological progression or change to 3rd line systemic therapy or death or loss to follow-up, whichever comes first.

  2. Acute and Late Toxicities

    Time frame: 1 year

    For SBRT combined with TKI (using CTCAE Version 5.0)

  3. Reported Adverse Events

    Time frame: 1 year

    PRO-CTCAE Questionnaire

  4. Quality of Life Outcome

    Time frame: 1 year

    QLQ-LC13 Questionnaire

  5. Quality of Life Outcome

    Time frame: 1 year

    EORTC-QLQ-C15 Questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

C. Jillian Tsai

CONTACT

[email protected]

416-946-4501 ext. 4866

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Official study title

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor

Acronym: CURB-TKI

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 7, 2025
Registry last updated
Aug 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.